Axsome Therapeutics/$AXSM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
- Ticker
- $AXSM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,390
- Headquarters
- New York, United States
- Website
- www.axsome.com
AXSM Metrics
BasicAdvanced
$6.8B
-
-$3.05
0.83
-
Price and volume
Market cap
$6.8B
Beta
0.83
52-week high
$260.19
52-week low
$123.00
Average daily volume
1.1M
Financial strength
Current ratio
1.422
Quick ratio
1.289
Long term debt to equity
1.404
Total debt to equity
2.127
Interest coverage (TTM)
-12.65%
Profitability
EBITDA (TTM)
-152.798
Gross margin (TTM)
93.25%
Net profit margin (TTM)
-18.18%
Operating margin (TTM)
-18.88%
Effective tax rate (TTM)
-0.41%
Revenue per employee (TTM)
$620,000
Management effectiveness
Return on assets (TTM)
-13.65%
Return on equity (TTM)
-175.59%
Valuation
Price to revenue (TTM)
7.729
Price to book
64.73
Price to tangible book (TTM)
118.4
Price to free cash flow (TTM)
-80.954
Free cash flow yield (TTM)
-1.24%
Free cash flow per share (TTM)
-1.603
Growth
Revenue change (TTM)
54.16%
Earnings per share change (TTM)
-34.53%
3-year revenue growth (CAGR)
57.03%
3-year earnings per share growth (CAGR)
-12.39%
10-year earnings per share growth (CAGR)
8.97%
What the Analysts think about AXSM
Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.
Analyst projections of the future price of Axsome Therapeutics stock.
Bulls say / Bears say
Third-quarter revenue rose 52% year on year to $259.7 million, with AUVELITY sales up 53% to $207.6 million. That strong commercial growth gives Axsome a larger revenue base to build on. (BioSpace)
AUVELITY’s new Alzheimer’s disease agitation indication adds another potential growth market. After its June launch, new-to-brand prescriptions among patients aged 65 and over rose 126% in the first eight weeks compared with the previous quarter’s equivalent period. (SEC)
The pipeline offers further potential catalysts: Axsome expected Phase 3 results for solriamfetol in binge-eating disorder in the fourth quarter of 2026, and the FDA set a 1 May 2027 decision date for its AXS-12 narcolepsy application. (SEC)
AUVELITY accounts for about 80% of revenue, leaving results heavily dependent on one medicine and exposed if its growth slows or competition increases. (Investing.com)
Axsome remains loss-making despite rapid sales growth. In the second quarter, SG&A rose to $208.1 million from $130.3 million a year earlier and the company reported a $51.3 million net loss. (SEC)
Pipeline growth is uncertain and takes time: AXS-12 still awaits an FDA decision, while Axsome expects enrolment in its Phase 3 AXS-14 fibromyalgia trial to finish only in the third quarter of 2027. Delays or disappointing results could push out the next sources of product growth. (BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
AXSM Financial Performance
Revenues and expenses
AXSM Earnings Performance
Company profitability
Upcoming events
No upcoming events
AXSM News
AllArticlesVideos
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
MarketBeat4 days ago
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction
MarketBeat2 months ago
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
MarketBeat2 months ago
Funds containing AXSM
AllUSDEURGBP
Fund name | Fund size | $AXSM weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.52% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.52% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.52% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.45% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.45% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.